Sen. Collins must know insulin alone is not enough | Letter

Letter to Editor Calls for Broad Health Reform Ahead of Maine Election

A South Portland resident’s letter to the Maine Press Herald has sparked discussion about the state’s upcoming 2026 election, as the writer critiques Senator Susan Collins’s recent praise of the federal Insulin Affordability Act and urges voters to focus on wider health‑care policies.

The letter, posted on July 29, 2026, was written by Ann Morrill, a mother from South Portland, who argues that a single‑drug measure does little for people with chronic conditions such as type 1 diabetes. Morrill says her son—who was diagnosed with the disease at nine years old—has learned firsthand that insulin, while essential, is only one piece of a larger puzzle that includes glucose monitors, test strips, lab tests, and regular doctor visits.

“Having raised a child to adulthood who developed Type 1 diabetes at age 9, I can assure everyone that the cost of insulin, while necessary for life, is but a very small part of what these children need,” Morrill wrote. She points out that once a teen ages out of parental coverage, they face the daunting task of securing health insurance while also pursuing education or employment. “Affordable health insurance then becomes life‑defining,” she added.

Morrill’s criticism focuses on Senator Susan Collins of Maine, who recently issued a press statement celebrating the passage of the Insulin Affordability Act. In that statement, Collins described the bill as a “step closer to affordable insulin for all Americans.” Morrill calls the senator’s tone “self‑congratulatory back‑patting” and frames the legislation as a “single‑drug” approach that fails to address the broader health‑care needs of people with chronic diseases.

The letter also references Collins’s past voting record, specifically her opposition to President Barack Obama’s Affordable Care Act (ACA). Collins voted to defeat the ACA in 2010 and has consistently worked against a government‑run public option for health insurance. Morrill uses this history to challenge Collins’s claim that she cares about children with chronic illnesses, arguing that “it became perfectly clear that she actually cared not one whit for these children she professed to be concerned about.”

Beyond the specifics of insulin, Morrill asks whether the United States should pursue “a sane and effective way to regulate healthcare” by focusing on one drug rather than a comprehensive system. She urges voters to consider whether the country should adopt a model similar to other developed nations that provide equitable access to health‑care for all citizens. “Come Election Day, voters should look at whose policies will be most beneficial for all, and vote accordingly,” she wrote.

The Insulin Affordability Act, signed into law by President Joe Biden in late 2024, is designed to reduce the cost of insulin for patients by allowing Medicare to negotiate prices and capping out‑of‑pocket spending for insulin users. While the bill is a notable step, health‑policy analysts point out that it does not address the overall affordability of medications or the cost of ancillary supplies required by patients with diabetes.

Morrill’s letter arrives as Maine heads into its 2026 election cycle, with state and national races set to be decided in November. The issue of health‑care coverage and drug pricing is likely to be a prominent topic in campaign debates, as voters weigh the merits of candidates’ plans for expanding coverage and controlling prescription costs.

In the broader national context, the ACA remains a point of contention, with several states still debating the extent to which they will adopt the federal framework or pursue alternative models. Collins’s long‑standing opposition to the public option reflects a broader ideological divide on how best to provide health insurance in the United States.

The letter has drawn attention from both supporters of the Insulin Affordability Act and critics who argue that it does not go far enough. Some commenters on the Press Herald’s online platform praised Morrill for highlighting the complexities of managing type 1 diabetes, while others defended Collins’s record, citing her support for bipartisan health‑care initiatives and her efforts to bring a more measured approach to drug pricing.

For voters in Maine, the discussion underscores the importance of evaluating candidates’ positions on health policy beyond single‑issue bills. Morrill’s plea for a holistic approach to health coverage echoes a growing sentiment among consumers who feel that the current system disproportionately benefits pharmaceutical companies at the expense of patients.

As the 2026 election approaches, the Press Herald’s coverage of health‑care reform in Maine is expected to intensify, with candidates likely to outline their plans for expanding insurance coverage, reducing prescription costs, and ensuring that medical supplies remain affordable for all residents. Morrill’s letter serves as a reminder that, for many voters, the stakes are not only the price of insulin but the broader question of what a fair, comprehensive health‑care system looks like in America.